What We Do

Auspex Diagnostics focuses on developing and providing advanced cancer diagnostics services to medical professionals and patients to help them personalize cancer treatment plans and improve patients’ quality of living.

Our Mission

By leveraging advanced data analytics technologies, we aim to provide cancer patients and oncologists the necessary tools to help them make the best data-driven treatment decisions and improve the quality of care.


We started developing the technology in 2001, and conducted preliminary research between 2001 and 2005 at the Rutgers Cancer Institute of New Jersey. The result of the study helped to validate that big data analytic models can be used to predict efficacy of certain cancer treatments. This discover was the basis of personalize medicine.

Expression Genomics of Cervical Cancer, Clinical Cancer Research, Vol 9, Issue 15, 5462-5492 Nov 15, 2003
Our research suggests that response to radiotherapy can be predicted by monitoring the expression profiles of some of these cervical cancers, which were stratified into responders and nonresponders, based on the retrospective outcome of the treatment.

Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling, Cancer Genetics and Cytogenetics, Volume 154, Issue 1, (October 2004), 63-66

Since 2003 Auspex has partnered with the Taipei Veterans General Hospital (TVGH), one of the leading research hospitals in Taiwan,  in the research and development of our predictive model. In 2007 we were rewarded the Small Business Innovation Research (SBIR) grants from the Ministry of Economic Affairs of Taiwan, and commenced collaboration with the Industrial Technology Research Institute (ITRI).